A pragmatic guide for management of adverse events associated with lorlatinib

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2  % to 7 % of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international gui delines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].

Source: Lung Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Geoffrey Liu, Julien Mazieres, Jan Stratmann, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J. Solomon, Todd M. Bauer Tags: Review article Source Type: research